132 related articles for article (PubMed ID: 37097697)
21. Dose optimization of fractionated external radiation and high-dose-rate intracavitary brachytherapy for FIGO stage IB uterine cervical carcinoma.
Lee SW; Suh CO; Chung EJ; Kim GE
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1338-44. PubMed ID: 11955747
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.
Saglam O; Zhou J; Wang X; Conejo-Garcia JR
Int J Gynecol Pathol; 2020 Sep; 39(5):428-435. PubMed ID: 31274701
[TBL] [Abstract][Full Text] [Related]
23. Postoperative radiotherapy in early stage carcinoma of the uterine cervix: treatment results and prognostic factors.
Yeh SA; Wan Leung S; Wang CJ; Chen HC
Gynecol Oncol; 1999 Jan; 72(1):10-5. PubMed ID: 9889023
[TBL] [Abstract][Full Text] [Related]
24. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).
Toita T; Kato S; Niibe Y; Ohno T; Kazumoto T; Kodaira T; Kataoka M; Shikama N; Kenjo M; Tokumaru S; Yamauchi C; Suzuki O; Sakurai H; Numasaki H; Teshima T; Oguchi M; Kagami Y; Nakano T; Hiraoka M; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e49-56. PubMed ID: 21470794
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic value of T lymphocytes infiltration in breast cancer].
Yu HM; Jiao SC; Yang JL; Wang JD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):199-206. PubMed ID: 23643010
[TBL] [Abstract][Full Text] [Related]
27. High dose-rate brachytherapy for elderly patients with uterine cervical cancer.
Chen SW; Liang JA; Yang SN; Lin FJ
Jpn J Clin Oncol; 2003 May; 33(5):221-8. PubMed ID: 12865465
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
30. A prognostic model using FIGO 2018 staging and MRI-derived tumor volume to predict long-term outcomes in patients with uterine cervical squamous cell carcinoma who received definitive radiotherapy.
Zang L; Chen Q; Lin A; Chen J; Zhang X; Fang Y; Wang M
World J Surg Oncol; 2023 Jul; 21(1):210. PubMed ID: 37475053
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
32. Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial).
Googe PB; Theocharis S; Pergaris A; Li H; Yan Y; McKenna EF; Moschos SJ
Curr Probl Cancer; 2022 Jun; 46(3):100862. PubMed ID: 35398635
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma.
Zhu Y; Li M; Bo C; Liu X; Zhang J; Li Z; Zhao F; Kong L; Yu J
Cancer Immunol Immunother; 2017 Mar; 66(3):343-354. PubMed ID: 27915370
[TBL] [Abstract][Full Text] [Related]
34. The role of systemic inflammatory response index (SIRI) and tumor-infiltrating lymphocytes (TILs) in the prognosis of patients with laryngeal squamous cell carcinoma.
Wang T; Zhang D; Tang D; Heng Y; Lu LM; Tao L
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5627-5636. PubMed ID: 36520215
[TBL] [Abstract][Full Text] [Related]
35. Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma.
Hoesli R; Birkeland AC; Rosko AJ; Issa M; Chow KL; Michmerhuizen NL; Mann JE; Chinn SB; Shuman AG; Prince ME; Wolf GT; Bradford CR; McHugh JB; Brenner JC; Spector ME
Oral Oncol; 2018 Feb; 77():83-89. PubMed ID: 29362129
[TBL] [Abstract][Full Text] [Related]
36. Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Dimitrakopoulos FI; Goussia A; Koliou GA; Dadouli K; Batistatou A; Kourea HP; Bobos M; Arapantoni-Dadioti P; Tzaida O; Koletsa T; Chrisafi S; Sotiropoulou M; Papoudou-Bai A; Nicolaou I; Charchanti A; Mauri D; Aravantinos G; Binas I; Res E; Psyrri A; Pectasides D; Bafaloukos D; Koumarianou A; Bompolaki I; Rigakos G; Karanikiotis C; Koutras A; Zagouri F; Gogas H; Fountzilas G
Breast; 2024 Feb; 73():103668. PubMed ID: 38176305
[TBL] [Abstract][Full Text] [Related]
37. Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma.
Hu WH; Miyai K; Cajas-Monson LC; Luo L; Liu L; Ramamoorthy SL
J Surg Oncol; 2015 Sep; 112(4):421-6. PubMed ID: 26287957
[TBL] [Abstract][Full Text] [Related]
38. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
